More Articles

US Supreme Court looks set to challenge Affordable Care Act Biosimilars/General | Posted 18/05/2012

The United States Supreme Court is reviewing the constitutionality of the provision in the Affordable Care Act providing that individuals should take personal responsibility for paying for their he...

Clopidogrel goes off-patent: last of the old-style blockbusters Generics/General | Posted 18/05/2012

The blockbuster drug Plavix (clopidogrel), used to prevent clotting in some heart patients, comes off patent in the US on 17 May 2012, bringing to an end the run of spectacularly well-selling tradi...

Biosimilars marketed in Europe Reports | Posted 18/05/2012

Europe was the first region to approve and introduce biosimilars into the market back in 2006, and now in 2012 the continent is the largest biosimilars market in the world, with 14 biosimilars appr...

Mexican biocomparables guidelines come into force Guidelines | Posted 18/05/2012

The Federal Commission for the Protection Against Sanitary Risks (COFEPRIS) announced on 20 April 2012 that the Mexican guidelines for biocomparables had come into force.

Generic atorvastatin could save NHS GBP 350 million a year Generics/News | Posted 18/05/2012

Generics of Pfizer’s blockbuster cholesterol treatment Lipitor (atorvastatin) could save the National Health Service (NHS) in the UK a whopping GBP 250 million or more during the coming years, foll...

IMS Health enlisted as information provider for drug shortages Pharma News | Posted 18/05/2012

The Generic Pharmaceutical Association (GPhA) announced on 19 April 2012 that it had selected IMS Health (IMS) to serve as the Independent Third Party in the Accelerated Recovery Initiative (ARI),...

Biosimilars approved and marketed in Belgium Biosimilars/General | Posted 18/05/2012

Last updated: 18 May 2012 The Federal Agency for Medicines and Health Products (FAMHP), formerly the Directorate-General for Medicinal Products of the Federal Public Service (FPS) Public Healt...

Daiichi Sankyo and Coherus BioSciences make biosimilars deal Biosimilars/News | Posted 18/05/2012

Coherus BioSciences and Daiichi Sankyo announced on 7 May 2012 that the two companies had made an exclusive agreement to develop and commercialise biosimilars of etanercept and rituximab in certain...